Yibai Pharmaceutical: Participated in the centralized procurement of diclofenac and other drugs by Guangdong Alliance to be selected_ Securities Times Network

Securities Times e company news, Yibai Pharmaceutical announced on the evening of March 13 that recently, Changan Pharmaceutical, a subsidiary of the company, participated in the bidding of Guangdong Alliance for the centralized procurement of diclofenac and other drugs. Changan Pharmaceutical’s product Loboplatin for Injection is planned to be selected for this centralized procurement. The specification of the product to be selected: 10mg (calculated as anhydrous), the price to be selected: 359.1928 yuan; the proposed price of lobaplatin for injection of this Changan Pharmaceutical product is 18% lower than the original benchmark price. The agreement and implementation will help to further expand the sales scope of the selected products and increase the market share of the selected products.